dose-response inhibition model for neutralization assay with graphpad prism7 software Search Results


graphpad prism 7.00  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.00
Graphpad Prism 7.00, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.00/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.00 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism 7.02  (GraphPad Software Inc)
90
GraphPad Software Inc prism 7.02
Prism 7.02, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 7.02/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 7.02 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphpad prism 7.02  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.02
Graphpad Prism 7.02, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.02/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.02 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmoidal dose–response stimulation (with variable slope)  (GraphPad Software Inc)
90
GraphPad Software Inc sigmoidal dose–response stimulation (with variable slope)
Sigmoidal Dose–Response Stimulation (With Variable Slope), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmoidal dose–response stimulation (with variable slope)/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
sigmoidal dose–response stimulation (with variable slope) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
three-parameter dose-response curves graphpad prism 7.02  (GraphPad Software Inc)
90
GraphPad Software Inc three-parameter dose-response curves graphpad prism 7.02
Three Parameter Dose Response Curves Graphpad Prism 7.02, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/three-parameter dose-response curves graphpad prism 7.02/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
three-parameter dose-response curves graphpad prism 7.02 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmoidal dose response curve graphpad prism 7  (GraphPad Software Inc)
90
GraphPad Software Inc sigmoidal dose response curve graphpad prism 7
Sigmoidal Dose Response Curve Graphpad Prism 7, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmoidal dose response curve graphpad prism 7/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
sigmoidal dose response curve graphpad prism 7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dose-response curve graphpad prism 7.05  (GraphPad Software Inc)
90
GraphPad Software Inc dose-response curve graphpad prism 7.05
Dose Response Curve Graphpad Prism 7.05, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dose-response curve graphpad prism 7.05/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
dose-response curve graphpad prism 7.05 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
3 parameter dose response inhibition function  (GraphPad Software Inc)
90
GraphPad Software Inc 3 parameter dose response inhibition function
3 Parameter Dose Response Inhibition Function, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3 parameter dose response inhibition function/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
3 parameter dose response inhibition function - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphpad prism7 software  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism7 software
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Graphpad Prism7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism7 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism7 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
variable slope (4 parameter) sigmoidal dose-response model equation  (GraphPad Software Inc)
90
GraphPad Software Inc variable slope (4 parameter) sigmoidal dose-response model equation
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Variable Slope (4 Parameter) Sigmoidal Dose Response Model Equation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/variable slope (4 parameter) sigmoidal dose-response model equation/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
variable slope (4 parameter) sigmoidal dose-response model equation - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmoidal dose–response curves graphpad prism 7.0 software  (GraphPad Software Inc)
90
GraphPad Software Inc sigmoidal dose–response curves graphpad prism 7.0 software
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Sigmoidal Dose–Response Curves Graphpad Prism 7.0 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmoidal dose–response curves graphpad prism 7.0 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
sigmoidal dose–response curves graphpad prism 7.0 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphpad prism 7.0247  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.0247
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Graphpad Prism 7.0247, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.0247/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.0247 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.

Journal: Scientific Reports

Article Title: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

doi: 10.1038/s41598-019-39510-w

Figure Lengend Snippet: Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.

Article Snippet: Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses.

Techniques: MTT Assay, Concentration Assay, Software